Obesity Management – ICER

Apr, 11th 2019 9:55 am, Article Recommended by Dr. J. Smith

CTAF, Washington State

It is estimated that more than one-third of American adults and about 17% of adolescents are obese. The health effects of obesity are myriad and include the development of type 2 diabetes,hypertension, cardiovascular disease, cancer, high blood pressure, and sleep apnea. Obesity and itssequelae are estimated to generate $147 billion in health care costs in the US alone. The complexity involved in managing obesity may affect both patient candidacy for certain treatmentoptions as well as adherence to lifestyle changes necessary to sustain weight loss and improve healthoutcomes. Clinical interest is therefore high in treatments that may be used for patients atmultiple levels of obesity, as well as in interventions that promote better adherence to lifestyle change.

Interventions of interest:

Devices Temporary intragastric balloon systems (e.g., Silimed, ReShape) Vagus nerve block devices (e.g., Maestro system) Duodenal-jejunal bypass liner (EndoBarrier)Medications Naltrexone/bupropion sustained-release (Contrave) Phentermine/topiramate extended-release (Qsymia) Lorcaserin (Belviq) Liraglutide (Saxenda)

Date of review: May 2015

Intervention of interest:

Roux-en-Y gastric bypass (RYGB) Biliopancreatic diversion/duodenal switch (BPD/DS) Laparoscopic adjustable gastric banding (LAGB) Vertical sleeve gastrectomy (VSG)

Date of review: April2015

View post:
Obesity Management – ICER